Kawakami, H., Kadowaki, S., Makiyama, A., Tsuda, M., Hirata, K., Sugimoto, N., Machida, N., Hara, H., Hirano, H., Esaki, T., Komatsu, Y., Hironaka, S., Kobayashi, Y., Kakimi, K., Chiba, Y., Boku, N., Hyodo, I., Muro, K. (2025). Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-02463